GenSight Biologics S.A. is a clinical-stage biotechnology firm dedicated to pioneering, advancing, and bringing to market treatments for serious eye and central nervous system disorders, specifically those linked to mitochondrial dysfunction and neurodegeneration. Their therapeutic pipeline is built upon cutting-edge gene therapy approaches, including mitochondrial targeting sequences and optogenetics technologies. The company's primary drug candidate, LUMEVOQ (GS010), is a recombinant AAV2-based gene therapy currently undergoing Phase III clinical evaluation for Leber hereditary optic neuropathy (LHON) stemming from a specific ND4 gene mutation. Another key candidate, GS030, is in Phase I/II trials for retinitis pigmentosa and is also being investigated in preclinical studies for dry age-related macular degeneration. Beyond these, GenSight is also advancing a range of other preclinical programs aimed at addressing various ophthalmic and neurodegenerative conditions. Established in 2012, GenSight Biologics S.A. operates from its headquarters in Paris, France.
—
GenSight Biologics S.A. is a clinical-stage biotechnology firm dedicated to pioneering, advancing, and bringing to market treatments for serious eye and central nervous system disorders, specifically those linked to mitochondrial dysfunction and neurodegeneration. Their therapeutic pipeline is built upon cutting-edge gene therapy approaches, including mitochondrial targeting sequences and optogenetics technologies. The company's primary drug candidate, LUMEVOQ (GS010), is a recombinant AAV2-based gene therapy currently undergoing Phase III clinical evaluation for Leber hereditary optic neuropathy (LHON) stemming from a specific ND4 gene mutation. Another key candidate, GS030, is in Phase I/II trials for retinitis pigmentosa and is also being investigated in preclinical studies for dry age-related macular degeneration. Beyond these, GenSight is also advancing a range of other preclinical programs aimed at addressing various ophthalmic and neurodegenerative conditions. Established in 2012, GenSight Biologics S.A. operates from its headquarters in Paris, France.
—
Daily adjusted close
GenSight Biologics S.A. is a clinical-stage biotechnology firm dedicated to pioneering, advancing, and bringing to market treatments for serious eye and central nervous system disorders, specifically those linked to mitochondrial dysfunction and neurodegeneration. Their therapeutic pipeline is built upon cutting-edge gene therapy approaches, including mitochondrial targeting sequences and optogenetics technologies. The company's primary drug candidate, LUMEVOQ (GS010), is a recombinant AAV2-based gene therapy currently undergoing Phase III clinical evaluation for Leber hereditary optic neuropathy (LHON) stemming from a specific ND4 gene mutation. Another key candidate, GS030, is in Phase I/II trials for retinitis pigmentosa and is also being investigated in preclinical studies for dry age-related macular degeneration. Beyond these, GenSight is also advancing a range of other preclinical programs aimed at addressing various ophthalmic and neurodegenerative conditions. Established in 2012, GenSight Biologics S.A. operates from its headquarters in Paris, France.